Raymond James & Associates Has $1.73 Million Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Raymond James & Associates reduced its position in G1 Therapeutics, Inc. (NASDAQ:GTHX) by 38.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 565,555 shares of the company’s stock after selling 360,221 shares during the quarter. Raymond James & Associates’ holdings in G1 Therapeutics were worth $1,725,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. increased its position in G1 Therapeutics by 6.7% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 53,625 shares of the company’s stock worth $408,000 after purchasing an additional 3,383 shares during the last quarter. Ergoteles LLC increased its holdings in shares of G1 Therapeutics by 10.5% during the 1st quarter. Ergoteles LLC now owns 36,200 shares of the company’s stock valued at $275,000 after acquiring an additional 3,446 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of G1 Therapeutics by 24.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,497 shares of the company’s stock valued at $243,000 after acquiring an additional 3,872 shares during the last quarter. Credit Suisse AG increased its holdings in shares of G1 Therapeutics by 11.6% during the 1st quarter. Credit Suisse AG now owns 38,602 shares of the company’s stock valued at $103,000 after acquiring an additional 4,013 shares during the last quarter. Finally, Engineers Gate Manager LP increased its holdings in shares of G1 Therapeutics by 21.6% during the 3rd quarter. Engineers Gate Manager LP now owns 26,361 shares of the company’s stock valued at $329,000 after acquiring an additional 4,674 shares during the last quarter. 24.21% of the stock is owned by institutional investors and hedge funds.

Insider Activity at G1 Therapeutics

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares in the company, valued at approximately $785,113.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.23% of the stock is owned by corporate insiders.

G1 Therapeutics Price Performance

Shares of NASDAQ:GTHX opened at $4.28 on Thursday. The business has a 50 day moving average price of $3.64 and a 200 day moving average price of $2.85. G1 Therapeutics, Inc. has a twelve month low of $1.08 and a twelve month high of $5.00. The company has a market cap of $223.54 million, a price-to-earnings ratio of -4.51 and a beta of 1.73. The company has a quick ratio of 3.45, a current ratio of 3.87 and a debt-to-equity ratio of 1.46.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, February 28th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The firm had revenue of $14.87 million during the quarter, compared to the consensus estimate of $12.83 million. During the same quarter in the prior year, the company earned ($0.73) EPS. Research analysts predict that G1 Therapeutics, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GTHX. Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush reissued an “outperform” rating and set a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.